

Julie M Gastier-Foster

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9684262/publications.pdf>

Version: 2024-02-01

114
papers

28,529
citations

50276

46
h-index

27406

106
g-index

114
all docs

114
docs citations

114
times ranked

43697
citing authors

#	ARTICLE	IF	CITATIONS
1	Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. <i>Genetics in Medicine</i> , 2015, 17, 405-424.	2.4	20,455
2	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. <i>Cell Systems</i> , 2018, 6, 271-281.e7.	6.2	605
3	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. <i>Nature Genetics</i> , 2015, 47, 864-871.	21.4	451
4	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2019, 51, 296-307.	21.4	384
5	Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. <i>Journal of Clinical Oncology</i> , 2016, 34, 2380-2388.	1.6	301
6	Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. <i>Blood</i> , 2015, 126, 964-971.	1.4	287
7	Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2015, 6, 6604.	12.8	281
8	Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. <i>Nature Genetics</i> , 2013, 45, 1494-1498.	21.4	264
9	A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor. <i>Nature Genetics</i> , 2017, 49, 1487-1494.	21.4	255
10	Recurrent DGCR8, DROSHA, and SIX Homeodomain Mutations in Favorable Histology Wilms Tumors. <i>Cancer Cell</i> , 2015, 27, 286-297.	16.8	244
11	Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. <i>Blood</i> , 2017, 129, 3352-3361.	1.4	236
12	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2016, 7, 13331.	12.8	218
13	Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALLO622. <i>Journal of Clinical Oncology</i> , 2018, 36, 2306-2314.	1.6	185
14	IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients. <i>Blood</i> , 2015, 125, 3501-3508.	1.4	177
15	Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2021, 39, 3229-3241.	1.6	174
16	Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. <i>Blood</i> , 2019, 133, 1313-1324.	1.4	172
17	Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALLO434 Methotrexate Randomization. <i>Journal of Clinical Oncology</i> , 2018, 36, 2926-2934.	1.6	164
18	Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. <i>Lancet Oncology</i> , The, 2015, 16, 1659-1666.	10.7	161

#	ARTICLE	IF	CITATIONS
19	Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 11306-11311.	7.1	151
20	Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. JAMA Oncology, 2020, 6, 724.	7.1	139
21	Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2020, 38, 3282-3293.	1.6	136
22	A multicenter study of the frequency and distribution of GJB2 and GJB6 mutations in a large North American cohort. Genetics in Medicine, 2007, 9, 413-426.	2.4	134
23	<i>TP53</i> Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. Journal of Clinical Oncology, 2018, 36, 591-599.	1.6	121
24	Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell, 2016, 29, 186-200.	16.8	118
25	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood, 2015, 125, 680-686.	1.4	110
26	Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. Journal of Clinical Oncology, 2020, 38, 602-612.	1.6	107
27	Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design. Cell Reports, 2019, 29, 1675-1689.e9.	6.4	103
28	Association of <i>MYCN</i> copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Cancer, 2017, 123, 4224-4235.	4.1	97
29	Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. Blood, 2018, 132, 815-824.	1.4	97
30	Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol <i>Escherichia coli</i> L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4. Journal of Clinical Oncology, 2014, 32, 3874-3882.	1.6	91
31	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	2.9	90
32	Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. Nature, 2018, 553, 511-514.	27.8	90
33	A Genome-Wide Scan Identifies Variants in <i>NFIB</i> Associated with Metastasis in Patients with Osteosarcoma. Cancer Discovery, 2015, 5, 920-931.	9.4	88
34	Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. Journal of Clinical Oncology, 2018, 36, 1564-1570.	1.6	87
35	Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident. Science, 2021, 372, .	12.6	85
36	Significance of <i>TP53</i> Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group. Clinical Cancer Research, 2016, 22, 5582-5591.	7.0	82

#	ARTICLE	IF	CITATIONS
37	Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26645.	1.5	82
38	Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1176-1183.	1.5	76
39	Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. <i>Nature Communications</i> , 2015, 6, 7553.	12.8	72
40	Variant Interpretation for Dilated Cardiomyopathy. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e002480.	3.6	70
41	<i>Phf6</i> Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL. <i>Cancer Discovery</i> , 2019, 9, 436-451.	9.4	67
42	Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. <i>Cancer Cell</i> , 2021, 39, 38-53.e7.	16.8	65
43	Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 2527-2534.	1.6	64
44	Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. <i>Journal of Clinical Oncology</i> , 2019, 37, 3243-3255.	1.6	61
45	COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10500-10500.	1.6	54
46	Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2016, 63, 634-639.	1.5	53
47	Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2019, 37, 780-789.	1.6	48
48	TCF21 hypermethylation in genetically quiescent clear cell sarcoma of the kidney. <i>Oncotarget</i> , 2015, 6, 15828-15841.	1.8	46
49	Variability in pathogenicity prediction programs: impact on clinical diagnostics. <i>Molecular Genetics & Genomic Medicine</i> , 2015, 3, 99-110.	1.2	44
50	Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. <i>Blood</i> , 2019, 133, 724-729.	1.4	44
51	Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG). <i>Leukemia</i> , 2018, 32, 1370-1379.	7.2	40
52	Analysis of Ugandan cervical carcinomas identifies human papillomavirus clade-specific epigenome and transcriptome landscapes. <i>Nature Genetics</i> , 2020, 52, 800-810.	21.4	40
53	Molecular basis of <i>ETV6</i> -mediated predisposition to childhood acute lymphoblastic leukemia. <i>Blood</i> , 2021, 137, 364-373.	1.4	37
54	Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group. <i>Cancer Genetics</i> , 2019, 238, 62-68.	0.4	32

#	ARTICLE	IF	CITATIONS
55	Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. <i>Nature Cancer</i> , 2020, 1, 1113-1127.	13.2	32
56	Genome-wide association study identifies the <i>GLDC</i> / <i>IL33</i> locus associated with survival of osteosarcoma patients. <i>International Journal of Cancer</i> , 2018, 142, 1594-1601.	5.1	31
57	MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MK1 neuroblastomas: a report from the Children's oncology group. <i>Oncotarget</i> , 2018, 9, 6416-6432.	1.8	31
58	Noncoding genetic variation in <i>GATA3</i> increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation. <i>Nature Genetics</i> , 2022, 54, 170-179.	21.4	29
59	Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26928.	1.5	28
60	Transcriptome analysis of desmoplastic small round cell tumors identifies actionable therapeutic targets: a report from the Children's Oncology Group. <i>Scientific Reports</i> , 2020, 10, 12318.	3.3	28
61	Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 10011-10011.	1.6	25
62	The College of American Pathologists Biorepository Accreditation Program: Results from the First 5 Years. <i>Biopreservation and Biobanking</i> , 2018, 16, 16-22.	1.0	23
63	Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2015, 21, 4733-4739.	7.0	21
64	Neurodevelopmental disorders among individuals with duplication of 4p13 to 4p12 containing a GABAA receptor subunit gene cluster. <i>European Journal of Human Genetics</i> , 2014, 22, 105-109.	2.8	20
65	Germline <i>RUNX1</i> variation and predisposition to childhood acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	20
66	Favorable Trisomies and <i>ETV6-RUNX1</i> Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331. <i>Journal of Clinical Oncology</i> , 2021, 39, 1540-1552.	1.6	19
67	Outcome of Children with Standard-Risk Lineage Acute Lymphoblastic Leukemia: Comparison among Different Treatment Strategies. <i>Pediatric Blood and Cancer</i> , 2016, 63, 255-261.	1.5	17
68	Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group. <i>Blood Advances</i> , 2019, 3, 1647-1656.	5.2	17
69	The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. <i>Journal of the National Cancer Institute</i> , 2021, 113, 27-37.	6.3	17
70	Association of <i>GATA3</i> Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2021, 113, 408-417.	6.3	16
71	Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children's Oncology Group (COG) Study AALL0331. <i>Blood</i> , 2014, 124, 793-793.	1.4	15
72	Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 490.e1-490.e8.	1.2	14

#	ARTICLE	IF	CITATIONS
73	Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group. <i>European Journal of Cancer</i> , 2020, 133, 112-119.	2.8	13
74	Genomic analysis of adult B-ALL identifies potential markers of shorter survival. <i>Leukemia Research</i> , 2017, 56, 44-51.	0.8	12
75	Genotype-phenotype correlation: Inheritance and variant-type infer pathogenicity in IQSEC2 gene. <i>European Journal of Medical Genetics</i> , 2020, 63, 103735.	1.3	12
76	Two Distinct Subsets of dic(9;12)(p12;p11.2) among Children with B-Cell Precursor Acute Lymphoblastic Leukemia (ALL): PAX5-ETV6 and ETV6-RUNX1 Rearrangements: A Report from the Children's Oncology Group. <i>Blood</i> , 2007, 110, 1439-1439.	1.4	12
77	Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Haematologica</i> , 2019, 104, e517-e520.	3.5	11
78	A slowly progressive form of limb-girdle muscular dystrophy type 2C associated with founder mutation in the <i>SGCG</i> gene in Puerto Rican Hispanics. <i>Molecular Genetics & Genomic Medicine</i> , 2015, 3, 92-98.	1.2	10
79	Genetic Characterization of Pediatric Sarcomas by Targeted RNA Sequencing. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 1238-1245.	2.8	9
80	Outcomes of dasatinib plus intensive chemotherapy or stem cell transplant (SCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) on Children's Oncology Group AALL0622. <i>Journal of Clinical Oncology</i> , 2015, 33, 10006-10006.	1.6	9
81	No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27681.	1.5	8
82	Expanding the spectrum of <i>CEP55</i> -associated disease to viable phenotypes. <i>American Journal of Medical Genetics, Part A</i> , 2020, 182, 1201-1208.	1.2	8
83	Blood collection in cell-stabilizing tubes does not impact germline DNA quality for pediatric patients. <i>PLoS ONE</i> , 2017, 12, e0188835.	2.5	8
84	Genome sequencing identifies somatic BRAF duplication c.1794_1796dupTAC;p.Thr599dup in pediatric patient with low-grade ganglioglioma. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002618.	1.2	7
85	Response to Biesecker and Harrison. <i>Genetics in Medicine</i> , 2018, 20, 1689-1690.	2.4	7
86	Masked Hypodiploidy: Hypodiploid Acute Lymphoblastic Leukemia (ALL) in Children Mimicking Hyperdiploid ALL: A Report From the Children's Oncology Group (COG) AALL03B1 Study. <i>Blood</i> , 2009, 114, 1580-1580.	1.4	7
87	Atypical breakpoint in a t(6;17) translocation case of acampomelic campomelic dysplasia. <i>European Journal of Medical Genetics</i> , 2014, 57, 315-318.	1.3	6
88	Samovar: Single-Sample Mosaic Single-Nucleotide Variant Calling with Linked Reads. <i>IScience</i> , 2019, 18, 1-10.	4.1	6
89	Retrospective clinical trial experimentally validates glioblastoma genome-wide pattern of DNA copy-number alterations predictor of survival. <i>APL Bioengineering</i> , 2020, 4, 026106.	6.2	5
90	Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2015, 126, 807-807.	1.4	5

#	ARTICLE	IF	CITATIONS
91	The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 649-649.	1.4	5
92	Outcomes of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Based on Blast Genotype at Diagnosis: A Report from the Children's Oncology Group. <i>Blood</i> , 2016, 128, 451-451.	1.4	4
93	Assessment of end induction minimal residual disease (MRD) in childhood B precursor acute lymphoblastic leukemia (ALL) to eliminate the need for day 14 marrow examination: A Children's Oncology Group study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10001-10001.	1.6	4
94	Relationship of fusion protein status and outcome for children with intermediate-risk rhabdomyosarcoma: A Children's Oncology Group report.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9535-9535.	1.6	3
95	Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Children's Oncology Group (COG) study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10528-10528.	1.6	3
96	An Educational Assessment of Evidence Used for Variant Classification. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 555-565.	2.8	3
97	International Laboratory Comparison of Methodologies for Determining Minimal Residual Disease (MRD) in Childhood Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL). <i>Blood</i> , 2015, 126, 2612-2612.	1.4	2
98	Germline Genetic Variation in ETV6 and Predisposition to Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 695-695.	1.4	2
99	Pericentromeric regions of homozygosity on the X chromosome: Another likely benign population variant. <i>European Journal of Medical Genetics</i> , 2018, 61, 416-420.	1.3	1
100	Children with NCI Standard Risk Acute Lymphoblastic Leukemia (ALL) and TEL-AML1 or Favorable Chromosome Trisomies Are Almost Certain to Be Cured with Graduated Intensity Therapy: Results of the CCG - 1991 Study.. <i>Blood</i> , 2009, 114, 320-320.	1.4	1
101	Genomic Analysis of Adult B-ALL Identifies Changes in Copy Number Profile at Relapse and IKZF1/CDKN2A Co-Deletion at Diagnosis As a Marker of Shorter Survival. <i>Blood</i> , 2015, 126, 1427-1427.	1.4	1
102	Comprehensive Functional Characterization of Germline ETV6 Variants Associated with Inherited Predisposition to Acute Lymphoblastic Leukemia in Children. <i>Blood</i> , 2016, 128, 1085-1085.	1.4	1
103	Burkitt Lymphoma Genome Sequencing Project (BLGSP): Introduction. <i>Blood</i> , 2016, 128, 1760-1760.	1.4	1
104	Minimal Residual Disease Assessment of Remission after Induction Therapy Is Superior to Morphologic Assessment for Risk Stratification in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2016, 128, 758-758.	1.4	1
105	The impact of initial cerebrospinal fluid (CSF) findings on outcome among patients with NCI standard (SR) and high-risk (HR) B-lymphoblastic leukemia (ALL): A report from the Children's Oncology Group (COG) Studies AALL0331 and AALL0232.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10016-10016.	1.6	1
106	Preliminary analysis of the mutational landscape of non-rhabdomyosarcoma soft tissue sarcoma: A Children's Oncology Group study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10510-10510.	1.6	1
107	A Genome-Wide Association Study of Susceptibility to Acute Lymphoblastic Leukemia in Adolescents and Young Adults. <i>Blood</i> , 2014, 124, 132-132.	1.4	1
108	A revised Children's Oncology Group (COG) neuroblastoma risk classification system: Report from the COG biology study ANBL00B1.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10012-10012.	1.6	1

#	ARTICLE	IF	CITATIONS
109	Reply to B. Zhang et al. Journal of Clinical Oncology, 2018, 36, 1454-1455.	1.6	0
110	Abstract 2118: Non-coding germline GATA3 variants alter chromatin topology and contribute to pathogenesis of acute lymphoblastic leukemia. , 2021, , .		0
111	Cryptic Truncating Rearrangements of the Erythropoietin Receptor in Ph-like Acute Lymphoblastic Leukemia. Blood, 2014, 124, 128-128.	1.4	0
112	Clinical application of prognostic gene expression signature in fusion gene-negative rhabdomyosarcoma: A report from the Childrenâ€™s Oncology Group.. Journal of Clinical Oncology, 2015, 33, 10510-10510.	1.6	0
113	RNA profiling of desmoplastic small round cell tumors (DSRCTs) using next-generation sequencing.. Journal of Clinical Oncology, 2016, 34, 10552-10552.	1.6	0
114	Mutational Landscape, Clonal Evolution Patterns and Role of RAS Mutations in Relapsed Acute Lymphoblastic Leukemia. Blood, 2016, 128, 4068-4068.	1.4	0